anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

216,181-216,240 of 319,975

filter-aware
16
The slide uses a timeline to map specific digital product categories to clinical development stages.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
17
The slide uses a process-oriented layout to describe the regulatory and commercialization pathway.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
18
The slide outlines the strategic rationale for a specific clinical trial phase.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
19
The slide outlines a clinical trial design (MMED007) using a timeline-based visualization.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
20
MindMed | Investor Presentation Deck | 32 slidesMindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
21
The slide uses a biological process diagram to explain the drug's mechanism of action (MOA).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
The slide uses a bar chart to bridge the gap between the problem (no drugs) and the solution (R(-)-MDMA alignment with patient needs).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
23
The slide uses a bar chart to demonstrate the therapeutic index advantage of the R-enantiomer.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
24
The chart shows improvement in social anxiety at 1 month and 6 months, indicating durability of effect.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
25
MindMed | Investor Presentation Deck | 32 slidesMindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
26
The slide highlights three pillars of collaboration: discovery engine, drug delivery, and clinical testing.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
27
The slide highlights a strategic partnership and the resulting research pipeline.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
28
The slide uses a grid layout to associate each executive with a set of logos representing their past experience.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Team1 hit
29
The slide highlights the depth of experience by listing previous company affiliations for each leader.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Team1 hit
30
The slide uses a logo-grid approach to establish credibility through past professional experience.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations Beat · Team1 hit
31
The slide uses a bulleted list format to highlight core business strengths and specific drug development programs (MM-120 and MM-402).MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
32
This appears to be a section divider or closing slide.MindMed | Investor Presentation Deck | 32 slides · MindMed
Pitch deck Investor relations 1 hit
01
Slide 1
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
02
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
03
The slide uses a generic pie chart graphic as a visual metaphor for market segmentation.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Logic Chain1 hit
04
Uses authority citation (Forbes) to establish the scale of the problem.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProblemLoop · Logic Chain1 hit
05
The slide uses a product photo to demonstrate the scale and form factor of the device.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
06
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
07
The slide uses a 'Target vs Status' framework to demonstrate progress.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
08
The slide outlines specific milestones including FDA approval, manufacturing scale-up, US market entry, and D2C expansion.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
09
The slide presents two line charts: one comparing BGM vs Invasive CGM, and one showing raw sugarBEAT data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · ProductLoop · Logic Chain1 hit
10
The slide highlights the UI/UX of the companion app for the sugarBEAT CGM device.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
11
The slide uses a pie chart graphic as a visual metaphor for market segmentation, though it does not contain actual data.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
12
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
13
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
14
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
15
The superscript 3 in '2000^3' appears to be a typo or formatting error in the source slide.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
16
The slide contrasts a large incumbent's metrics with the company's own USP.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations Beat · Competition1 hit
17
The slide outlines CE marking in Europe and the ongoing FDA PMA review process, including specific audit and inspection history.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
18
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
19
The slide uses a numbered list format to present future product roadmap items.Nemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
20
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
21
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
22
Nemaura Medical | Investor Presentation Deck | 22 slidesNemaura Medical | Investor Presentation Deck | 22 slides · Nemaura Medical
Pitch deck Investor relations 1 hit
01
Slide 1
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
02
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
03
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
04
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
05
Neumora Therapeutics | IPO Presentation Deck | 32 slidesNeumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Setup1 hit
06
The slide is split into two sections: Leadership (with headshots and bios) and Blue Chip Investors (with logos).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
07
The slide uses a Gantt-style chart to visualize clinical trial progress for seven distinct programs.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
08
Includes a detailed biological mechanism diagram showing the interaction of KOR, dynorphin, and neurotransmitters.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Solution1 hit
09
The slide uses a comparative structure to justify the strategic shift in trial design post-acquisition.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
10
Graphs depict prespecified statistical sensitivity analysis for moderate-to-severe patients (n=100; baseline HAMD-17 >= 22).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The table displays statistical significance (p-values) for multiple clinical endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
12
TEAE = Treatment-Emergent Adverse Events. Data compares Navacaprant vs Placebo (n=102 each).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · EvidenceLoop · Jobs To Be Done1 hit
13
Includes a timeline diagram for the randomized, double-blind treatment phase and a summary table of inclusion criteria and endpoints.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
14
The table uses a color-coded legend for 'Degree of preference' (High, Medium, Low).Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
15
Includes qualitative expert testimonials regarding pricing and market access.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank Beat · Market Sizing1 hit
16
The diagram illustrates a decision-tree process based on clinical trial outcomes.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
17
Includes a biological pathway diagram showing V1aR antagonism and downstream signaling effects.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
18
The slide uses a 'Signal Seeking' framework to justify clinical development decisions based on effect size.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
19
The slide uses a biological pathway diagram to illustrate the mechanism of action of the drug candidate.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
20
The table compares key metrics like EC50, half-life, brain:plasma ratio, selectivity, bioavailability, and molecular weight.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit
21
The slide uses a biological pathway diagram to illustrate the mechanism of action (PAM) and the pathology of schizophrenia.Neumora Therapeutics | IPO Presentation Deck | 32 slides · Neumora Therapeutics
Pitch deck Investment bank 1 hit